Pharma-Bio Serv, Inc.
PBSV
$0.59
$0.024.07%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.35% | -14.75% | -25.46% | -36.50% | -43.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.35% | -14.75% | -25.46% | -36.50% | -43.99% |
| Cost of Revenue | -12.90% | -21.82% | -28.05% | -36.30% | -41.29% |
| Gross Profit | 15.66% | 6.19% | -18.85% | -36.98% | -50.34% |
| SG&A Expenses | -6.73% | -9.18% | -7.59% | -8.01% | -3.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.73% | -17.69% | -21.92% | -28.62% | -31.92% |
| Operating Income | 50.47% | 44.44% | -111.78% | -368.62% | -215.23% |
| Income Before Tax | 87.54% | 85.64% | -317.69% | -157.09% | -144.76% |
| Income Tax Expenses | -71.95% | -155.73% | -105.71% | -95.73% | -94.14% |
| Earnings from Continuing Operations | 87.08% | 89.97% | -3,403.70% | -181.29% | -159.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.08% | 89.97% | -3,403.70% | -181.29% | -159.35% |
| EBIT | 50.47% | 44.44% | -111.78% | -368.62% | -215.23% |
| EBITDA | 54.29% | 47.56% | -120.84% | -335.08% | -208.48% |
| EPS Basic | 87.32% | 90.19% | -2,633.33% | -181.58% | -159.47% |
| Normalized Basic EPS | 87.32% | 85.51% | -312.00% | -156.65% | -144.57% |
| EPS Diluted | 86.71% | 89.57% | -1,680.00% | -184.09% | -160.70% |
| Normalized Diluted EPS | 87.32% | 85.51% | -312.00% | -156.65% | -144.57% |
| Average Basic Shares Outstanding | -0.10% | -0.10% | -0.07% | -0.04% | -0.01% |
| Average Diluted Shares Outstanding | -0.11% | -0.11% | -0.11% | -0.13% | -0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -6.73% | -8.96% | 0.97% | -2.23% | -2.68% |